Cargando…

Adenosine and inosine exert cytoprotective effects in an in vitro model of liver ischemia-reperfusion injury

Liver ischemia represents a common clinical problem. In the present study, using an in vitro model of hepatic ischemia-reperfusion injury, we evaluated the potential cytoprotective effect of the purine metabolites, such as adenosine and inosine, and studied the mode of their pharmacological actions....

Descripción completa

Detalles Bibliográficos
Autores principales: MÓDIS, KATALIN, GERŐ, DOMOKOS, STANGL, RITA, ROSERO, OLIVÉR, SZIJÁRTÓ, ATTILA, LOTZ, GÁBOR, MOHÁCSIK, PETRA, SZOLECZKY, PETRA, COLETTA, CIRO, SZABÓ, CSABA
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3981016/
https://www.ncbi.nlm.nih.gov/pubmed/23232950
http://dx.doi.org/10.3892/ijmm.2012.1203
_version_ 1782479618125594624
author MÓDIS, KATALIN
GERŐ, DOMOKOS
STANGL, RITA
ROSERO, OLIVÉR
SZIJÁRTÓ, ATTILA
LOTZ, GÁBOR
MOHÁCSIK, PETRA
SZOLECZKY, PETRA
COLETTA, CIRO
SZABÓ, CSABA
author_facet MÓDIS, KATALIN
GERŐ, DOMOKOS
STANGL, RITA
ROSERO, OLIVÉR
SZIJÁRTÓ, ATTILA
LOTZ, GÁBOR
MOHÁCSIK, PETRA
SZOLECZKY, PETRA
COLETTA, CIRO
SZABÓ, CSABA
author_sort MÓDIS, KATALIN
collection PubMed
description Liver ischemia represents a common clinical problem. In the present study, using an in vitro model of hepatic ischemia-reperfusion injury, we evaluated the potential cytoprotective effect of the purine metabolites, such as adenosine and inosine, and studied the mode of their pharmacological actions. The human hepatocellular carcinoma-derived cell line HepG2 was subjected to combined oxygen-glucose deprivation (COGD; 0-14-24 h), followed by re-oxygenation (0-4-24 h). Adenosine or inosine (300–1,000 μM) were applied in pretreatment. Cell viability and cytotoxicity were measured by the 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide and lactate dehydrogenase methods, respectively. The results showed that both adenosine and inosine exerted cytoprotective effects, and these effects were not related to receptor-mediated actions, since they were not prevented by selective adenosine receptor antagonists. On the other hand, the adenosine deaminase inhibitor erythro-9-(2-hydroxy-3-nonyl) adenine hydrochloride (EHNA, 10 μM) markedly and almost fully reversed the protective effect of adenosine during COGD, while it did not influence the cytoprotective effect of inosine in the same assay conditions. These results suggest that the cytoprotective effects are related to intracellular actions, and, in the case of adenosine also involve intracellular conversion to inosine. The likely interpretation of these findings is that inosine serves as an alternative source of energy to produce ATP during hypoxic conditions. The protective effects are also partially dependent on adenosine kinase, as the inhibitor 4-amino-5-(3-bromophenyl)-7-(6-morpholino-pyridin-3-yl)pyrido[2,3-d]pyrimidine, 2HCl (ABT 702, 30 μM) significantly reversed the protective effect of both adenosine and inosine during hypoxia and re-oxygenation. Collectively, the current results support the view that during hypoxia, adenosine and inosine exert cytoprotective effects via receptor-independent, intracellular modes of action, which, in part, depend on the restoration of cellular bioenergetics. The present study supports the view that testing of inosine for protection against various forms of warm and cold liver ischemia is relevant.
format Online
Article
Text
id pubmed-3981016
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-39810162014-04-09 Adenosine and inosine exert cytoprotective effects in an in vitro model of liver ischemia-reperfusion injury MÓDIS, KATALIN GERŐ, DOMOKOS STANGL, RITA ROSERO, OLIVÉR SZIJÁRTÓ, ATTILA LOTZ, GÁBOR MOHÁCSIK, PETRA SZOLECZKY, PETRA COLETTA, CIRO SZABÓ, CSABA Int J Mol Med Articles Liver ischemia represents a common clinical problem. In the present study, using an in vitro model of hepatic ischemia-reperfusion injury, we evaluated the potential cytoprotective effect of the purine metabolites, such as adenosine and inosine, and studied the mode of their pharmacological actions. The human hepatocellular carcinoma-derived cell line HepG2 was subjected to combined oxygen-glucose deprivation (COGD; 0-14-24 h), followed by re-oxygenation (0-4-24 h). Adenosine or inosine (300–1,000 μM) were applied in pretreatment. Cell viability and cytotoxicity were measured by the 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide and lactate dehydrogenase methods, respectively. The results showed that both adenosine and inosine exerted cytoprotective effects, and these effects were not related to receptor-mediated actions, since they were not prevented by selective adenosine receptor antagonists. On the other hand, the adenosine deaminase inhibitor erythro-9-(2-hydroxy-3-nonyl) adenine hydrochloride (EHNA, 10 μM) markedly and almost fully reversed the protective effect of adenosine during COGD, while it did not influence the cytoprotective effect of inosine in the same assay conditions. These results suggest that the cytoprotective effects are related to intracellular actions, and, in the case of adenosine also involve intracellular conversion to inosine. The likely interpretation of these findings is that inosine serves as an alternative source of energy to produce ATP during hypoxic conditions. The protective effects are also partially dependent on adenosine kinase, as the inhibitor 4-amino-5-(3-bromophenyl)-7-(6-morpholino-pyridin-3-yl)pyrido[2,3-d]pyrimidine, 2HCl (ABT 702, 30 μM) significantly reversed the protective effect of both adenosine and inosine during hypoxia and re-oxygenation. Collectively, the current results support the view that during hypoxia, adenosine and inosine exert cytoprotective effects via receptor-independent, intracellular modes of action, which, in part, depend on the restoration of cellular bioenergetics. The present study supports the view that testing of inosine for protection against various forms of warm and cold liver ischemia is relevant. D.A. Spandidos 2013-02 2012-12-04 /pmc/articles/PMC3981016/ /pubmed/23232950 http://dx.doi.org/10.3892/ijmm.2012.1203 Text en Copyright © 2013, Spandidos Publications http://creativecommons.org/licenses/by/3.0 This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Articles
MÓDIS, KATALIN
GERŐ, DOMOKOS
STANGL, RITA
ROSERO, OLIVÉR
SZIJÁRTÓ, ATTILA
LOTZ, GÁBOR
MOHÁCSIK, PETRA
SZOLECZKY, PETRA
COLETTA, CIRO
SZABÓ, CSABA
Adenosine and inosine exert cytoprotective effects in an in vitro model of liver ischemia-reperfusion injury
title Adenosine and inosine exert cytoprotective effects in an in vitro model of liver ischemia-reperfusion injury
title_full Adenosine and inosine exert cytoprotective effects in an in vitro model of liver ischemia-reperfusion injury
title_fullStr Adenosine and inosine exert cytoprotective effects in an in vitro model of liver ischemia-reperfusion injury
title_full_unstemmed Adenosine and inosine exert cytoprotective effects in an in vitro model of liver ischemia-reperfusion injury
title_short Adenosine and inosine exert cytoprotective effects in an in vitro model of liver ischemia-reperfusion injury
title_sort adenosine and inosine exert cytoprotective effects in an in vitro model of liver ischemia-reperfusion injury
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3981016/
https://www.ncbi.nlm.nih.gov/pubmed/23232950
http://dx.doi.org/10.3892/ijmm.2012.1203
work_keys_str_mv AT modiskatalin adenosineandinosineexertcytoprotectiveeffectsinaninvitromodelofliverischemiareperfusioninjury
AT gerodomokos adenosineandinosineexertcytoprotectiveeffectsinaninvitromodelofliverischemiareperfusioninjury
AT stanglrita adenosineandinosineexertcytoprotectiveeffectsinaninvitromodelofliverischemiareperfusioninjury
AT roserooliver adenosineandinosineexertcytoprotectiveeffectsinaninvitromodelofliverischemiareperfusioninjury
AT szijartoattila adenosineandinosineexertcytoprotectiveeffectsinaninvitromodelofliverischemiareperfusioninjury
AT lotzgabor adenosineandinosineexertcytoprotectiveeffectsinaninvitromodelofliverischemiareperfusioninjury
AT mohacsikpetra adenosineandinosineexertcytoprotectiveeffectsinaninvitromodelofliverischemiareperfusioninjury
AT szoleczkypetra adenosineandinosineexertcytoprotectiveeffectsinaninvitromodelofliverischemiareperfusioninjury
AT colettaciro adenosineandinosineexertcytoprotectiveeffectsinaninvitromodelofliverischemiareperfusioninjury
AT szabocsaba adenosineandinosineexertcytoprotectiveeffectsinaninvitromodelofliverischemiareperfusioninjury